Group 1: Recent IPOs - Daoyuan Group, a diversified consulting and fintech solutions provider from Macau, successfully listed on NASDAQ, raising $6 million by issuing 1.5 million shares, with a market capitalization of $32.09 million [1] - Dahon Technology, a folding bicycle company from Shenzhen, successfully listed on the Hong Kong Stock Exchange, raising HKD 392 million by issuing 7.92 million shares, with a market capitalization of HKD 1.57 billion [2] Group 2: Companies Filing for IPO - Banjet Electronics, an automotive wireless sensor SoC company from Shanghai, filed for an IPO on the Hong Kong Stock Exchange, recognized as the third-largest globally and the largest in China in its sector [3] - Sige New Energy, a renewable energy solutions provider from Shanghai, refiled for an IPO on the Hong Kong Stock Exchange after a previous application expired, aiming to lead in distributed energy storage systems with a projected market share of 28.6% in 2024 [4] - Fokang Pharmaceutical, a biopharmaceutical company from Shanghai focused on breakthrough therapies for cancer and viral diseases, filed for an IPO on the Hong Kong Stock Exchange [5] - Shengwei Times, a city road passenger transport information service provider from Shanghai, refiled for an IPO on the Hong Kong Stock Exchange, aiming to enhance digital solutions in the transport sector [6] - Barentsz, a management and technology consulting firm from Hong Kong, submitted an IPO application to the SEC for a NASDAQ listing, planning to raise approximately $5 million [7] - EvoNexus, a mobile application developer from Hong Kong, filed for an IPO on NASDAQ, aiming to raise $8 million by issuing 2 million shares [8] Group 3: Upcoming IPOs - Hesai Technology, a lidar research and manufacturing company, is set to offer 2.55 million shares from September 8 to September 11, aiming to raise approximately HKD 4.16 billion, with a listing expected on September 16 [9] - Health 160, a digital healthcare service provider, plans to offer 33.6455 million shares from September 9 to September 12, targeting a maximum fundraising of HKD 500 million, with a listing expected on September 17 [10] - Jinfang Pharmaceutical, a biopharmaceutical company, will offer 77.6 million shares from September 11 to September 16, aiming to raise approximately HKD 1.582 billion, with a listing expected on September 19 [11] Group 4: Market Developments - NASDAQ submitted a proposal to the SEC to allow trading of tokenized securities, which would integrate traditional and blockchain finance, potentially implemented by Q3 2026 [12] - The upcoming Hong Kong Policy Address is expected to propose a phased reduction or elimination of stock stamp duty and reforms to the Growth Enterprise Market, aimed at enhancing market vitality [13]

务，公示期不少于 10 天。 股东大会审议本激励计划前 5 日披露监事会对激励对象名单审核及公示情况的 说明。经公司董事会调整的激励对象名单亦应经公司监事会核实。 （四）激励对象获授的股票期权分配情况 本激励计划授予的股票期权在各激励对象间的分配情况如下表所示： 占授予股 占本激励计划公 获授的股票期权 姓名 职务 票期权总 告时公司股本总 数量（份） 量的比例 额的比例 彭政纲 董事长 185,000 1.22% 0.01% 范径武 副董事长、总裁 222,000 1.46% 0.01% 蒋建圣 董事 125,500 0.83% 0.01% 官晓岚 副总经理 67,500 0.45% 0.00% 张永 副总经理 173,000 1.14% 0.01% 张国强 副总经理 154,000 1.02% 0.01% 方晓明 副总经理 137,000 0.90% 0.01% 王锋 副总经理 121,500 0.80% 0.01% 肖敏 董事会秘书 95,000 0.63% 0.01% 姚曼英 财务负责人 97,000 0.64% 0.01% 董事及高管合计 1,377,500 9.09% 0.07% 核心管理、技术、 ...